The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

A class of sheltered COVID pundits are eager to conjure an alternate history where we let the virus spread in 2020 and everything turned out just fine.

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...